Mariner
XLO icon

Mariner’s Xilio Therapeutics XLO Stock Holding History

Mariner’s Portfolio XLO Stock Details XLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,786
Closed -$16K – 3861
2025
Q4 		$16K Hold
1,786
– – ﹤0.01% 3493
2025
Q3 		$21.1K Hold
1,786
– – ﹤0.01% 3511
2025
Q2 		$17K Hold
1,786
– – ﹤0.01% 3434
2025
Q1 		$18.1K Hold
1,786
– – ﹤0.01% 3384
2024
Q4 		$23.9K Sell
1,786
-22
-1% -$303 ﹤0.01% 3344
2024
Q3 		$19.9K Buy
+1,808
New +$22.2K ﹤0.01% 3248

Other funds holding XLO

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Mariner's XLO Position: Q1 2026 in Review

Mariner sold out of Xilio Therapeutics (XLO) in Q1 2026, closing a stake of 1,786 shares — an estimated $16K sold.

Mariner first reported a position in XLO in Q3 2024 and held it in 6 quarters. The position peaked at $23.9K in Q4 2024. 24 funds tracked by Wall St. Rank hold XLO as of Q1 2026.

  • Mariner reported no remaining Xilio Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Mariner sold 1,786 Xilio Therapeutics shares in Q1 2026, an estimated $16K.
  • Mariner first reported a position in Xilio Therapeutics in Q3 2024 and held it in 6 quarters.
  • Mariner's Xilio Therapeutics position peaked at $23.9K in Q4 2024.
  • 24 funds tracked by Wall St. Rank held Xilio Therapeutics as of Q1 2026.

Based on Mariner's 13F filing for Q1 2026, filed 13 May 2026.